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It is shown that in the presence of Ca*+ plasmin converts bovine fibrinogen fragment Dn (95 kDa) into DLA fragment 
by the cleavage of its B-chain Ark,,-Thr,,, bond. DLA fragment consists of two components (82 and 12 kDa) held to- 
gether by non-covalent bonds and has 3.5fold higher anticlotting activity than Dn fragment. The Da to DL* fragment 
conversion leads to the destabilization of thermolabile domains of the latter without the loss of their compact structure. 
The results obtained show that the activation of Da fragment by the cleavage of its Args,,-Thr,,, bond bears some resem- 
blance to the general activation of proenzyme into enzyme. 
Fragment Dn; Anticlotting activity; Proteolysis; Activation; Sequence homology 
1. INTRODUCTION 
The plasma protein fibrinogen is converted en- 
zymatically into fibrin to form a fibrin clot. In vivo 
the clot is broken down by the enzyme plasmin 
resulting in various soluble fragments, some of 
which inhibit fibrin assembly. Among them is 
Dtcatc) or Du (95 kDa) fragment. This fragment 
contains a number of polymerization sites by 
which it interacts with growing fibrin polymer thus 
terminating further polymerization. Further pro- 
teolysis of Dn fragment without Ca2+ leads to 
splitting of its C-terminal 1,3 kDa portion of y- 
chain, which forms one of the active sites [1,2]. 
This leads to the appearance of Duor~ or light DL 
(82 kDa) fragment, which has no anticlotting 
properties. Trypsin produces similar fragments, 
but on prolonged trypsin digestion of bovine 
fibrinogen in the presence of Ca2’ along with Du 
and DL fragments the DLZ fragment with unknown 
structure appears [3]. The latter (DL~) is a more po- 
tent inhibitor of the fibrin assembly process than 
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Du fragment [3]. The question arises as to the 
cause of the greater extent of the anticlotting 
properties of the active Dr.2 fragment (DLz). 
Here we present results demonstrating that Dn 
fragment can be converted into the more active 
DLA fragment by plasmin action. The results ob- 
tained allow clarification of the mechanism of in- 
creasing of Dn fragment anticlotting activity by 
limited plasminolysis. 
2. MATERIALS AND METHODS 
Bovine fibrinogen and fibrin monomer were prepared as 
described [4]. Fibrin-Sepharose was prepared as described [5]. 
DH fragment obtained from a 2 h plasmin hydrolysate of 
fibrinogen and purified by the method described [6]. Hydrolysis 
was performed in 0.1 M Tris-HCl, pH 7.4, with 0.15 M NaCl 
and 5 x lo-” M CaClr, at 25°C; protein was 20 mg/ml and 
plasmin activity was 0.2 caseinolytic units/ml. 
Clotting time was determined visually at 37°C in samples 
containing 0.05 M Tris-HCl buffer, pH 7.4, with 0.15 M NaCl, 
1 x low4 M CaClz and 0.3 mg/ml fibrin monomer. Anticlotting 
effect was presented as the (t - to)/&, ratio, where t and to are 
the clotting times of fibrin monomer in the presence and 
absence of inhibitor, respectively. The inhibitor activity of 
fragments was expressed in special units proposed by.Belitser et 
al. [7]. 
The M, values of the studied protein fragments were deter- 
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mined by high-speed equilibrium ultracentrifugation as de- 
scribed [8] and by SDS-polyacrylamide gel electrophoresis. 
Amino-terminal amino acid sequence was determined by the 
Dansyl chloride method [9]. 
Calorimetric studies were carried out on a scanning 
microcalorimeter (DASM-1M) as in [6]. 
3. RESULTS AND DISCUSSION 
Prolonged hydrolysis of DH fragment (specific 
anticlotting activity 13.3 units) by plasmin in the 
presence of Ca2+ leads to the formation of new 
products of 82 and 12 kDa (fig.1). The accumula- 
tion of these products is accompanied by the in- 
crease of anticlotting activity of hydrolysate up to 
33.4 units (fig.2). We inhibited 48 h hydrolysate by 
contrykal and passed it through the column with 
Lys-Sepharose to remove plasmin. Then hydro- 
lysate (30 mg) was applied to a column (3.6 x 
15 cm) with fibrin-Sepharose and fractionated as 
described [3]. As seen from fig.3, hydrolysate was 
separated into three fractions. Peak 2 contained 
Dn fragment (95 kDa) with anticlotting activity of 
13.3 units and peak 3 contained the fraction with 
higher affinity and anticlotting activity of 45.4 
units. The latter consisted of two bands of 82 kDa 
(as DJ_ fragment) and 12 kDa as revealed by SDS- 
electrophoresis (fig.4a). We have denoted it as ac- 
tive Dr fragment (DLA fragment). It is obvious that 
DLA fragment derives from Dn fragment and its 
appearance causes the increase of hydrolysate an- 
ticlotting activity. 
We have analyzed the structural organization of 
DLA fragment. As mentioned above, the SDS- 
electrophoretogram of this fragment shows two 
bands of 82 and 12 kDa (fig.4a). At the same time 
the molecular mass of the DLA fragment deter- 
mined by equilibrium ultracentrifugation is 94 + 
2 kDa, i.e., it corresponds to the sum of molecular 
masses of the two components revealed by SDS- 
electrophoresis. These components are not 
separated on a column (2.5 x 60 cm) of Sephadex 
G-75 SF in 0.1 M Tris-HCl buffer, pH 7.4, with 
0.15 or 2 M NaCl. Since the MI determination by 
SDS-electrophoresis was performed in denaturing 
conditions (0.1% SDS) and by equilibrium 
ultracentrifugation in non-denaturing conditions, 
one can conclude that native DLA fragment consists 
of two unequal components of 82 and 12 kDa link- 
ed together by non-covalent bonds. 
We have separated these components in denatur- 
Fig. 1. SDS-polyacrylamide gel electrophoretic patterns of timed 
plasmin digest of bovine DH fragment. Hydrolysis was 
performed in 0.1 M Tris-HCl, pH 7.4, with 0.15 M NaCl and 
5 x lo-’ M CaClr at 37°C; fragment was 2.5 mg/ml; plasmin 
activity was 1 .O caseinolytic units/ml. Electrophoresis was 
performed in 7% polyacrylamide gel as described [lo]. 
ing conditions (0.1 M Tris-HCI, pH 7.4, with 6 M 
urea) and analyzed their polypeptide chain com- 
position by SDS-electrophoresis with 2% ,& 
mercaptoethanol to reduce their S-S bonds. As 
seen from fig.4b, the 82 kDa component of DLA 
fragment, like Dn fragment, consists of three 
chains while the 12 kDa component is a one-chain 
fragment. An 82 kDa component reveals two 
bands of 38 and 12 kDa, which correspond to the 
y and LY chain of DH fragment, and double band ,B’ 
of 33 and 31.5 kDa. The double ,&‘-band cor- 
responds to the N-terminal remnants of Dn- 
fragment P-chain because they are linked with a 
and y-chains by disulphide bonds in the non- 
reduced 82 kDa component and contains a car- 
bohydrate as revealed by Schiff’s reagent staining 
of reduced patterns. It is likely that the 31.5 kDa 
component of the ,&’ -band is distinguished from 
the 33 kDa component by the absence of a small 
N-terminal polypeptide region. It is known that 
carbohydrate is attached to Asn371 of bovine 
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Fig.2. Anticlotting effect of the DH fragment (A), 24 h (0) 
and 48 h (0) hydrolysates of DH fragments and purified DLA 
fragment (A). 
fibrinogen P-chain [ 111, therefore P-chain (6’) of 
the 82 kDa component includes this amino acid 
residue. The 12 kDa component is a C-terminal 
remnant of Dn fragment P-chain because it has a 
typical tryptophan-like light absorption. spectrum, 
while the N-terminal portion of this chain with the 
same molecular mass contains no tryptophan [ 111. 
We have denoted it as PC-peptide. The N-terminal 
amino acids of PC-peptide found by us in two 
degradation cycles were Thr-Met. The amino acid 
z2 
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Fig.3. Affinity chromatography of a 48 h DH fragment 
hydrolysate on fibrin-Sepharose as described [3]. The 
replacement of elution buffers is indicated by arrows. 
Non-reduced Raduced, 
Fig.4. SDS-polyacrylamide gel electrophoretic patterns of 
fraction 2 (Dn fragment) and fraction 3 (DLA fragment) (a) and 
DH fragment (DH) and 82 kDa component of DLA fragment 
(DLA) with reduction of S-S bonds by 2% ,&mercaptoethanol 
(b). Electrophoresis was performed in 7% (a) and 10% (b) 
polyacrylamide gel as described [lo]. 
sequence analysis of bovine Dn-fragment P-chain 
shows that only cleavage of its Arg372-Thr373 pep- 
tide bond may produce a C-terminal fragment of 
12 kDa with N-terminal Thr-Met. It follows from 
the above that Dn fragment is converted into DLA 
fragment by the cleavage of its P-chain at the posi- 
tion of ArgsTz-Thr373. This conversion leads to a 
3.5fold increase in D-fragment anticlotting activi- 
ty. One can consider this process as the activation 
of Dn fragment by the proteolytic cleavage of the 
polypeptide chain. 
As was shown earlier [12], Dn fragment consists 
of five domains (fig.5b). The Arg372-Thr373 bond is 
situated between two interacting domains [ 131. It is 
clear that after cleavage of this bond @-peptide 
forming a single domain does not separate from 
the DLA fragment due to strong interaction with 
another domain. The question arises as to the 
structural changes on Dn to DLA fragment conver- 
sion, i.e. on activation of DH fragment. This ques- 
tion was clarified partly by the study of 
58 
Volume 232, number 1 FEBS LETTERS May 1988 
I LT I 
40 60 80 I00 
Temperature in “C 
Fig.5. Temperature dependence of the partial molar heat 
capacity function of the DH (a) and DLA fragment (b) in 0.05 M 
glycine (pH 3.5). Structure of DH fragment as described [12] 
and DLA fragment o be studied are given schematically in the 
upper right corner of both panels; the arrow indicates site of 
cleavage at DH to DLA conversion. 
denaturation processes of both these fragments. 
Fig.Sa and table 1 present calorimetrically ob- 
tained melting curves and thermodynamic 
characteristics of melting of DL~ and DH 
fragments. As seen, both fragments have high 
temperature (HT) and low temperature (LT) tran- 
Table 1 
sitions which correspond to the melting of their N- 
terminal coiled-coil and C-terminal globular 
regions, respectively [12]. The temperature and en- 
thalpies of HT transitions in both fragments are 
similar as are the ratios AIX$/AHi reflecting the 
number of melting domains. At the same time LT- 
domains in DLA fragment melt at 5°C lower 
temperature and with lower enthalpy. However, 
extrapolation of the enthalpy value for the DLA 
fragment to 45°C via the equation: 
T 
A&(T) = AH,,,(Tm) + j A,C,dT 
T, 
where A&, = 22 f 2 kJ - K-' . mol-’ is the ex- 
perimental value, gives a value for AH,(T, = 
45°C) = 1113 kJ-K-‘.mol-‘, which is very close 
to the value for the AH,,, of DH fragment (table 1). 
It follows that DH to DLA fragment conversion is 
accompanied by the destabilization of ther- 
molabile (LT) domains of the latter without loss of 
their compact structure. 
It should be noted that Lys-plasminogen activa- 
tion, which consists of cleavage of only the 
Argziao-Val561 peptide bond, leads to a similar 
destabilization of the domain, forming an active 
site [ 141. Pepsinogen to pepsin conversion is also 
accompanied by the destabilization of the pepsin 
structure [15]. It was tempting to suppose that the 
activation of DH fragment described in this paper 
is similar to proenzyme activation into enzyme. In 
this connection we have analyzed the activation 
process of some factors of the blood clotting 
system. It was found that on prothrombin activa- 
tion one of the bonds to be cleaved is Arg271-Thr272 
[16]. This bond is in the region ASp261-Phe281, 
Thermodynamic haracteristics of melting of the DH and DLA fragments 
Protein 
fragments 
Peak code 
LT HT 
T, AIt@ AH2 AH=‘/ 
A$ 
T,,, AH$ Ai!&’ AH$/ 
AHy,h 
DH (95 kDa) 45.0 1104 451 2.4 89.0 481 464 1.0 
DLA (82 + 12 kDa) 40.0 1003 422 2.4 89.0 468 460 1.0 
T,,,, temperature of peak maximum in “C; A%’ and AX!‘, calorimetric and van ‘t 
Hoff enthalpies in kJ .mol-‘. The experimental error does not exceed 5% 
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Fig.6. Diagram demonstrating homology between sequences in human prothrombin (a) and human and bovine fibrinogen Dn fragment 
@chains (b) in the 21-residue segment containing peptide bond Arg-Thr to be cleaved. Arrows indicate sites of cleavage by plasmin. 
which is highly homologous to the Glu362-Phe382 
region of bovine fibrinogen P-chain, containing 
the bond Args72-Thrs73 to be cleaved (fig.6). In 
both proteins these regions are situated between 
domains. Apparently these polypeptide chain 
segments evolved from the common protein 
module which was inserted into prothrombin and 
fibrinogen to ensure the realization of some of 
their similar properties, namely, activation by 
limited proteolysis. 
The data presented above show that the signifi- 
cant increase of the anticlotting activity of the Dn 
fragment after the cleavage of its Arg372-Thr37s 
bond is not a random phenomenon, but probably 
a physiologically important mechanism involved in 
the regulation of the fibrin clot formation process. 
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